XBiotech Inc.
For the period ended Dec 31, 2025. Filed Mar 13, 2026.
View on SEC.govAbout this filing
A company's yearly report to the SEC, with audited financial statements. It is the fullest account a company gives of its business, its finances and the risks it sees.
FY2025 · Filed Mar 13, 2026
XBIT$1.97+3.1%Stored close · as of Nov 10, 2026
Extracted filing text, with the paragraph anchors used by the comparison.
See the whole filing, with its images and exhibitsContents
Item 8. Consolidated Statements of Cash Flows
Consolidated Statements of Cash Flows
(in thousands)
| Year Ended December 31, | |||
|---|---|---|---|
| 2025 · 2024 | |||
| Operating activities | |||
| Net loss | $(45,540) | $(38,531) | |
| Adjustments to reconcile net loss to net cash used in operating activities: | |||
| Depreciation | 1,686 | 1,745 | |
| Deferred tax liability | 5 | - | |
| Foreign exchange (gain) loss | (3,333) | 5,529 | |
| Share-based compensation expense | 3,622 | 1,753 | |
| Changes in operating assets and liabilities: | |||
| Income tax receivable | 234 | (83) | |
| Accrued interest receivable | 340 | 160 | |
| Prepaid expenses and other current assets | (10) | (271) | |
| Accounts payable | (688) | (364) | |
| Accrued expenses | 3,686 | (877) | |
| Long term income tax payable | 78 | (24) | |
| Net cash used in operating activities | (39,920) | (30,963) | |
| Investing activities | |||
| Purchase of property and equipment | (289) | (1,304) | |
| Net cash used in investing activities | (289) | (1,304) | |
| Financing activities | |||
| (Payment on) proceeds from convertible loan related party | (10,000) | 10,000 | |
| (Payment on) proceeds from convertible loan, third party | (250) | 250 | |
| Issuance of common stock under stock option plan | - | 200 | |
| Net cash (used in) provided by financing activities | (10,250) | 10,450 | |
| Effect of foreign exchange rate on cash and cash equivalents | 3,333 | (5,529) | |
| Net change in cash and cash equivalents | (47,126) | (27,346) | |
| Cash and cash equivalents, beginning of year | 172,677 | 200,023 | |
| Cash and cash equivalents, end of year | $125,551 | $172,677 | |
| Supplemental Information: | |||
| Accrued purchases of property and equipment | $ | - | $70 |
| Cash paid for interest | $486 | $400 | |
| Cash paid (refunded) for income taxes | $(81) | $87 | |
The text of this filing, as the company filed it with the SEC, without its images or exhibits. This is not investment advice.